Clinical Trials

Are you at least 21 years old and have heart failure? In this clinical trial, researchers want to understand why patients with heart failure have trouble exercising and doing some of their daily activities. To take part, you must be taking medication to treat your heart failure for at least 30 days. People without heart failure can also join the study. Participants will have images (MRI) taken as part of the study. The study is taking place in Baltimore, Maryland.

Are you an adult who has uncontrolled high blood pressure? This study will see whether an early notification system for health professionals can help manage patients’ high blood pressure, especially among those who have had a stroke or have an increased risk of stroke. To participate in this study, you must be between 18 and 85 years old and have high blood pressure that is not controlled by medicine and lifestyle changes. This study is enrolling native English, Spanish, or Hmong speakers. The study is located in Minneapolis, Minnesota.

Do you have high blood pressure, and do you receive care at a community-based clinic in the South? This study will explore an intensive high blood pressure management approach at participating community-based clinics. The approach aims to lower participants’ systolic blood pressure to 120 mm Hg. To participate in this study, you must be at least 40 years old, understand English, and not be pregnant. The study is located in Louisiana, Alabama, and Mississippi.

DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 24-27 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.

This is an observational - data and specimen collection study. There have been increasing reports of vaping-induced lung injury, including severe lung injury and rare cases of death. The mechanism by which vaping contributes to lung injury in susceptible persons is unknown, as is impact on chronic lung disease. The investigators aim to identify individuals with chronic electronic nicotine delivery device (ENDD) exposure and matched controls within our ongoing cohort of HIV+ and HIV-uninfected individuals, collect PFT data, bank respiratory and stool samples and collect clinical data for studies of clinical risk, inflammation, biomarkers, and the microbiome in the identification and modification of risk of progression to lung injury or chronic pulmonary disease.

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

The purpose of this study is to evaluate whether biomarkers of lung injury and remodeling are responsive to effective continuous positive airway pressure (CPAP) treatment in adults with idiopathic pulmonary fibrosis (IPF) and moderate-to-severe obstructive sleep apnea (OSA).

Are you an adult who has idiopathic pulmonary fibrosis or an advanced lung cancer? This study aims to see whether a new imaging dye for positron emission tomography (PET) is effective at looking at fibrosis in lung cancer and idiopathic pulmonary fibrosis (IPF). Participants will be given the imaging dye and then receive a PET scan. To participate in this study, you must either be between 18 and 80 years old and have lung cancer or be a healthy volunteer or be between 50 and 80 years old and have IPF. This study is located in Boston, Massachusetts.

Are you between 40 and 85 with worsening idiopathic pulmonary fibrosis? This study aims to test a new combination treatment for acute exacerbations, a life-threatening complication of idiopathic pulmonary fibrosis (IPF) that has no approved treatment. The treatment is meant to help stop part of the immune system from further injuring the lung tissue. To participate in this study, you must be between 40 and 85 years old and have worsening IPF. This study is located in Birmingham, Alabama; Boston, Massachusetts; Philadelphia, Pennsylvania; and Pittsburgh, Pennsylvania.